Keytruda qlex 395 MG-4800 unit 2.4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEJ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $87,252
Award facts
- Contract value 100% obligated
- $87,251.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $87,251.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 395 mg in 2.4 mL vials. The award, issued on February 4, 2026, with an ultimate completion date of February 5, 2026, utilizes a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion enterprise-wide acquisition strategy established to support pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
The PPV-G GEN V contract awarded to DMS Pharmaceutical Group carries a $500 million ceiling value and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month extension periods. As a regional prime vendor contractor within this framework, DMS Pharmaceutical Group has demonstrated substantial performance across a diverse pharmaceutical portfolio encompassing oncology treatments, biologics, vaccines, and specialty medical products. The company's supply of Keytruda, a high-value oncology therapeutic, reflects its established capability to fulfill specialized pharmaceutical requirements critical to military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FMEJ2?
SPE2DR26FMEJ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FMEJ2 worth?
The government has obligated $87,252 on SPE2DR26FMEJ2.
Is contract SPE2DR26FMEJ2 an order under another contract?
Yes. SPE2DR26FMEJ2 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEJ2 competed?
The extent of competition for SPE2DR26FMEJ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award